GO:0042613 MHC class II protein complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042613 defines the MHC class II protein complex as a transmembrane heterodimer of an alpha and a beta chain that can bind peptide or polysaccharide antigen.
• MHC class II complexes are assembled in the endoplasmic reticulum with invariant chain and then traffic to endosomal compartments for peptide loading.
• The complex presents processed exogenous antigens to CD4+ T cells, a central event in adaptive immunity.
• Polymorphism in MHC class II genes shapes the repertoire of presented peptides and influences autoimmune and infectious disease susceptibility.
• Defects in MHC class II expression or function cause severe immunodeficiency and are linked to autoimmunity and cancer immune evasion.
• CRISPR-based knockout, knock-in, and overexpression models enable precise dissection of MHC class II complex biology in human cells.
Description
The MHC class II protein complex (GO:0042613) is a cell-surface and endosomal transmembrane heterodimer composed of an alpha chain and a beta chain that presents processed antigenic peptides to CD4+ T lymphocytes. This complex is the molecular platform for exogenous antigen presentation, a process essential for thymic selection, peripheral tolerance, and immune responses against pathogens. Because the genes encoding MHC class II chains are the most polymorphic in the human genome, the complex sits at the interface of host defense and autoimmunity. Researchers study GO:0042613 to understand how antigen processing, peptide loading, and T cell receptor recognition are coordinated, and to model diseases ranging from bare lymphocyte syndrome to rheumatoid arthritis and cancer. The complex is not a static entity; its assembly, trafficking, ubiquitination, and degradation are tightly regulated, making it a rich target for functional genomics and CRISPR screening.
MHC class II protein complex At A Glance
| GO ID | GO:0042613 |
|---|---|
| GO term | MHC class II protein complex |
| Ontology | cellular_component |
| Synonym | none |
| Definition | A transmembrane protein complex composed of an MHC class II alpha and MHC class II beta chain, and with or without a bound peptide or polysaccharide antigen. |
| Major function | Presentation of processed exogenous antigens to CD4+ T cells |
| Cellular location | Endosomal compartments, multivesicular bodies, and plasma membrane |
| Key subunits | MHC class II alpha chain and beta chain |
| Associated molecules | Invariant chain (CD74), HLA-DM, HLA-DO, CD83 |
What Is GO:0042613?
According to the Gene Ontology, GO:0042613 (MHC class II protein complex) is a transmembrane protein complex composed of an MHC class II alpha chain and an MHC class II beta chain, with or without a bound peptide or polysaccharide antigen. In practice, this means the term covers the alpha-beta heterodimer in all its states: empty, peptide-loaded, or bound to non-peptide antigens, as well as its membrane-embedded form in endosomes and at the plasma membrane.
Why Is MHC class II protein complex Important in Cell Biology?
The MHC class II protein complex is essential for adaptive immunity because it selects and displays peptides derived from endocytosed antigens to CD4+ T cells, thereby coordinating helper T cell activation, B cell help, and cytotoxic responses. Its polymorphism determines which peptides are presented, directly affecting susceptibility to infections and autoimmune diseases. Moreover, the complex is a therapeutic target in autoimmunity and a biomarker in cancer, where loss of MHC class II expression correlates with immune evasion. Understanding its assembly and regulation is therefore fundamental to immunology and translational medicine.
• Central to exogenous antigen presentation and CD4+ T cell priming.
• Polymorphism controls peptide repertoire and disease association.
• Defects cause MHC class II deficiency (bare lymphocyte syndrome).
• Involved in autoimmune diseases such as rheumatoid arthritis and type 1 diabetes.
• Modulated in tumors as a mechanism of immune escape.
• Target of bacterial superantigens that cross-link MHC class II and T cell receptors.
• Regulated by ubiquitination and endocytosis via March-I and CD83.
• Assembly requires invariant chain and HLA-DM for peptide editing.
• Exploited by pathogens to evade immune detection.
• Key model for studying membrane protein trafficking and quality control.
MHC class II protein complex: Components, Assembly and Research Methods
Assembly in the Endoplasmic Reticulum
In simple terms: The alpha and beta chains are made and paired in the ER with a helper protein called invariant chain.
MHC class II alpha and beta chains are co-translationally inserted into the endoplasmic reticulum membrane, where they fold and assemble into a heterodimer. The invariant chain (CD74) binds the alpha-beta dimer, preventing premature peptide binding and guiding the complex through the secretory pathway. Structural studies show that invariant chain interacts with the peptide-binding groove and the membrane-proximal regions of the heterodimer. This assembly step is critical for subsequent trafficking to endosomes.
Trafficking to Endosomal Compartments
In simple terms: The complex travels from the ER to endosomes where it meets antigens.
After assembly, the MHC class II-invariant chain complex is transported through the Golgi to late endosomal and lysosomal compartments, directed by signals in the invariant chain cytoplasmic tail. There, proteases progressively degrade the invariant chain, leaving a class II-associated invariant chain peptide (CLIP) in the groove. This trafficking route ensures that MHC class II encounters antigens derived from the endocytic pathway.
Peptide Loading and Editing
In simple terms: A specialized molecule swaps a placeholder peptide for real antigen fragments.
In endosomes, HLA-DM catalyzes the exchange of CLIP for high-affinity antigenic peptides, while HLA-DO can modulate HLA-DM activity in B cells. The resulting peptide-MHC class II complexes are then transported to the plasma membrane for surveillance by CD4+ T cells. The peptide repertoire displayed is influenced by MHC class II polymorphism and the available antigen pool.
T Cell Recognition and Signaling
In simple terms: T cells read the peptide-MHC complex and decide whether to respond.
CD4+ T cell receptors recognize peptide-MHC class II complexes with low affinity but high specificity, engaging coreceptors and triggering intracellular signaling. Structural and biophysical studies have defined how TCRs dock onto MHC class II and how polymorphism alters the interface. This recognition event is the cornerstone of helper T cell activation and immune coordination.
Regulation by Ubiquitination and Degradation
In simple terms: The complex can be tagged for removal from the surface, controlling how long it presents antigen.
MHC class II complexes are ubiquitinated by the E3 ligase March-I, leading to endocytosis and degradation, a process that tunes antigen presentation. CD83 suppresses March-I-dependent ubiquitination, thereby stabilizing MHC class II at the cell surface. This regulatory loop is important for dendritic cell maturation and immune homeostasis.
Key Genes Involved in GO:0042613 MHC class II protein complex
The following genes encode the major protein components and regulators of the MHC class II protein complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-DRA | MHC class II alpha chain | Core subunit; knockout abolishes complex formation |
| HLA-DRB1 | MHC class II beta chain | Most polymorphic; disease associations |
| HLA-DQA1 | MHC class II alpha chain | Pairs with DQB1; autoimmune risk |
| HLA-DQB1 | MHC class II beta chain | Peptide binding; type 1 diabetes risk |
| HLA-DPA1 | MHC class II alpha chain | Less polymorphic; antigen presentation |
| HLA-DPB1 | MHC class II beta chain | Transplant matching and disease |
| CD74 | Invariant chain; chaperone and trafficking | Knockout blocks peptide loading |
| HLA-DMA | Peptide editing catalyst | Required for CLIP exchange |
| HLA-DMB | Peptide editing catalyst | Works with HLA-DM |
| HLA-DOA | Modulator of HLA-DM | B cell-specific regulation |
| HLA-DOB | Modulator of HLA-DM | Fine-tunes peptide loading |
| CD83 | Stabilizes MHC class II by inhibiting March-I | Knockout increases degradation |
| MARCH1 | E3 ubiquitin ligase | Targets MHC class II for degradation |
| CIITA | Master transcriptional regulator | Knockout causes bare lymphocyte syndrome |
| RFX5 | Transcription factor for MHC class II | Defects cause immunodeficiency |
| RFXAP | Transcription factor for MHC class II | Defects cause immunodeficiency |
| RFXANK | Transcription factor for MHC class II | Defects cause immunodeficiency |
How Is MHC class II protein complex Regulated?
MHC class II complex levels are regulated transcriptionally by the master transactivator CIITA, which is controlled by interferon-gamma and other signals. Post-translationally, ubiquitination by March-I and its inhibition by CD83 control surface turnover and endocytosis. Peptide loading is regulated by HLA-DM and HLA-DO, which edit the peptide repertoire. These layers ensure that antigen presentation is context-dependent and tightly controlled.
MHC class II protein complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CIITA | MHC class II deficiency | Knockout in B cells or monocytes |
| HLA-DRB1 | Rheumatoid arthritis | Knock-in of risk allele in cell lines |
| HLA-DQB1 | Type 1 diabetes | Point mutation of peptide-binding pocket |
| CD83 | Immune regulation and autoimmunity | Overexpression and knockout in dendritic cells |
| MARCH1 | MHC class II degradation | Knockout to stabilize surface MHC II |
MHC Class II Deficiency (Bare Lymphocyte Syndrome)
Mutations in CIITA, RFX5, RFXAP, or RFXANK abolish MHC class II expression, causing severe combined immunodeficiency with recurrent infections and failure to thrive. This rare autosomal recessive disorder highlights the non-redundant role of the complex in human immunity.
Autoimmune Diseases
Polymorphisms in HLA-DRB1, HLA-DQA1, and HLA-DQB1 are strongly associated with rheumatoid arthritis, type 1 diabetes, and celiac disease, likely by altering peptide presentation and T cell selection. The MHC class II complex is therefore a key genetic determinant of autoimmunity.
Cancer Immune Evasion
Many tumors downregulate MHC class II to avoid CD4+ T cell recognition, and loss of expression correlates with poor prognosis. Understanding the complex's regulation may inform immunotherapies that restore antigen presentation.
Infectious Disease and Superantigens
Bacterial superantigens bind MHC class II and T cell receptors, causing massive cytokine release and toxic shock. Pathogens also manipulate MHC class II trafficking to evade immunity.
From MHC class II protein complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HLA-DRA abolish antigen presentation? | Knockout cell line (e.g., HeLa, HEK293) |
| How does a disease-associated HLA-DRB1 variant alter peptide binding? | Point mutation knock-in |
| Can a tagged MHC class II be tracked in live cells? | Knock-in of fluorescent tag |
| Does CD83 overexpression stabilize MHC class II? | Overexpression in dendritic cell lines |
| What genes regulate MHC class II surface levels? | CRISPR library screening |
| How does invariant chain deletion affect trafficking? | Knockout of CD74 |
How to Study the MHC class II protein complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface MHC class II levels | Phenotyping immune cells |
| Confocal microscopy | Subcellular localization | Trafficking studies |
| Immunoprecipitation-MS | Peptide repertoire and interactors | Immunopeptidomics |
| RNA-seq | Gene expression | Regulatory networks |
| CRISPR screen | Genes controlling presentation | Discovery of regulators |
| Crystallography/cryo-EM | 3D structure | TCR recognition and assembly |
| Ubiquitination assays | Post-translational modification | March-I regulation |
Flow Cytometry and Imaging
Flow cytometry with antibodies against HLA-DR, HLA-DP, and HLA-DQ quantifies surface MHC class II complexes, while confocal microscopy visualizes their endosomal trafficking. These methods are standard for assessing assembly and transport defects.
Immunoprecipitation and Proteomics
Immunoprecipitation of MHC class II followed by mass spectrometry identifies associated peptides and interacting proteins, revealing the immunopeptidome and assembly factors. This approach has been used to define invariant chain interactions.
Transcriptomics and CRISPR Screening
RNA-seq measures expression of MHC class II genes and regulators, while genome-wide CRISPR screens identify genes that control surface presentation. These methods are powerful for discovering novel regulators.
Structural Biology
X-ray crystallography and cryo-electron microscopy resolve the atomic details of MHC class II alone and in complex with TCRs or invariant chain, informing mechanism and drug design.
How CRISPR Can Be Used to Study GO:0042613 MHC class II protein complex
Knockout
CRISPR knockout of HLA-DRA, HLA-DRB1, or CD74 eliminates MHC class II complexes, providing a clean background to study antigen presentation and T cell activation. Knockout of CIITA or RFX factors models bare lymphocyte syndrome.
Point Mutation
Introducing disease-associated SNPs into HLA-DRB1 or HLA-DQB1 via CRISPR point mutation allows precise testing of how individual residues affect peptide binding and T cell recognition.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous HLA genes enables real-time tracking of MHC class II trafficking and assembly without overexpression artifacts.
Overexpression
Overexpression of CD83 or HLA-DM in cell lines can enhance or modulate MHC class II surface levels and peptide loading, useful for biochemical and functional studies.
How EDITGENE Supports MHC class II protein complex Research
Researchers studying MHC class II protein complex-related genes often need to determine whether a candidate gene is causally involved in assembly, trafficking, or antigen presentation. EDITGENE provides validated CRISPR tools and services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for MHC class II protein complex research.
Frequently Asked Questions About MHC class II protein complex
What is GO:0042613?
GO:0042613 is the Gene Ontology term for MHC class II protein complex, a transmembrane heterodimer of alpha and beta chains that presents antigens to CD4+ T cells.
What genes are involved in MHC class II protein complex?
Key genes include HLA-DRA, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1, HLA-DPB1, CD74, HLA-DMA, HLA-DMB, CD83, and CIITA.
What is the function of MHC class II protein complex?
It binds processed exogenous peptides and displays them on the cell surface for recognition by CD4+ T cell receptors, initiating adaptive immune responses.
Where is MHC class II protein complex located?
It is found in endosomal compartments, multivesicular bodies, and the plasma membrane of antigen-presenting cells.
What diseases are associated with MHC class II protein complex?
MHC class II deficiency, autoimmune diseases like rheumatoid arthritis and type 1 diabetes, and cancer immune evasion.
How is MHC class II protein complex regulated?
It is regulated transcriptionally by CIITA and post-translationally by ubiquitination via March-I and stabilization by CD83.
What is the role of invariant chain in MHC class II complex?
Invariant chain (CD74) binds the alpha-beta dimer, prevents premature peptide binding, and directs trafficking to endosomes.
How do CRISPR knockouts help study MHC class II?
Knockouts of HLA genes or CD74 eliminate the complex, allowing researchers to test its role in antigen presentation and T cell activation.
What is the difference between MHC class I and class II?
MHC class I presents endogenous peptides to CD8+ T cells, while MHC class II presents exogenous peptides to CD4+ T cells.
Can MHC class II be targeted for therapy?
Yes, modulating MHC class II expression or peptide loading is explored in autoimmunity and cancer immunotherapy.
Conclusion
The MHC class II protein complex (GO:0042613) is a cornerstone of adaptive immunity, integrating antigen processing, peptide loading, and T cell recognition. Its assembly and regulation are finely tuned, and its dysfunction underlies severe immunodeficiency, autoimmunity, and cancer immune evasion. CRISPR-based models are indispensable for dissecting these mechanisms and for developing targeted interventions.
References
- 1. Roche PA et al.. 2015. The ins and outs of MHC class II-mediated antigen processing and presentation.. Nat Rev Immunol 15(4):203-16 PMID: 25720354
- 2. Rossjohn J et al.. 2015. T cell antigen receptor recognition of antigen-presenting molecules.. Annu Rev Immunol 33:169-200 PMID: 25493333
- 3. Rudolph MG et al.. 2006. How TCRs bind MHCs, peptides, and coreceptors.. Annu Rev Immunol 24:419-66 PMID: 16551255
- 4. Hanna S et al.. 2014. MHC class I and II deficiencies.. J Allergy Clin Immunol 134(2):269-75 PMID: 25001848
- 5. Proft T et al.. 2007. Streptococcal superantigens.. Chem Immunol Allergy 93:1-23 PMID: 17369697
- 6. Kaul S et al.. 2025. CD83 suppresses endogenous March-I-dependent MHC class II ubiquitination, endocytosis, and degradation.. Proc Natl Acad Sci U S A 122(21):e2504077122 PMID: 40397676
- 7. Abualrous ET et al.. 2021. Major histocompatibility complex (MHC) class I and class II proteins: impact of polymorphism on antigen presentation.. Curr Opin Immunol 70:95-104 PMID: 34052735
- 8. Wang N et al.. 2024. Structural insights into human MHC-II association with invariant chain.. Proc Natl Acad Sci U S A 121(19):e2403031121 PMID: 38687785
